Inauguration of the New Viking Malt Production Plant in Lahti, Finland
23.5.2023 14:00:00 EEST | Business Wire | Press release
In Lahti, Finland on 23rd of May 2023 Viking Malt's new malting plant was officially inaugurated with a festive opening ceremony.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005582/en/
The capacity of the new malting plant is about 85 000 t/y and it replaces the old plant in Lahti. The new plant enables production of base malts, a wide selection of specialty malts as well as Sprau, Viking Malt's malted faba bean innovation. (Photo: Business Wire)
The capacity of the new malting plant is about 85 000 t/y and it replaces the old plant in Lahti. The new plant enables the production of base malts, a wide selection of specialty malts as well as Sprau, Viking Malt's malted faba bean innovation. In addition, the modern factory supports the sustainability strategy of Viking Malt with improved energy efficiency and a better working environment from a health and safety point of view.
“Building this new plant was a true team effort”, says the CEO Kasper Madsen, involving not only resources from the Viking Malt but also a range of suppliers and the support of our customers. Managing such a complex project in times disrupted by both a pandemic and a war requires strong and reliable partners.”
Pär-Gustaf Relander, owner and Chairman of the Board says that opening a new plant in Lahti, Finland, is a significant milestone in Viking Malt's history and a step forward in the company's long term strategy of building a sustainable business for the generations to come.
Viking Malt sells its products globally to the brewing, distilling and food industries. The company has a long history and is today owned by Polttimo representing the 5th generation of the same family, and Lantmännen. Polttimo is celebrating its 140 years anniversary this year. Throughout its history, it has survived and thrived by adaptability to changes in the operating environment, and a strong focus on quality and innovation.
Today, Viking Malt Group has production in 5 countries: Finland, Sweden, Denmark, Lithuania as well as two plants in Poland. The production capacity is 610 000 t/y and the turnover of the group is appr. 300 million euros. The group employs appr. 260 employees. Viking Malt is the largest malting company in the Baltic Rim, 5th largest in Europe and 9th in the world. It is amongst the leading companies in specialty malts in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).
More info about the company and products: www.vikingmalt.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005582/en/
Contact information
Additional information:
Pär-Gustaf Relander, Chairman of the Board, +358 50 552 3955
Kasper Madsen, CEO Viking Malt Group, +45 22 14 20 10
Pia Valve, VP HR and Communications Viking Malt Group +358 40 7700090
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 13:30:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,” to streamline medical documentation, staff scheduling, and promotional workflows. These initiatives are designed to improve per-clinic profitability. Furthermore, SBC Medical has secured priority sale
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 13:30:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medical was $16 million, up 22% year-over-year. Net income margin was 27%, a decrease of 3 percentage points year-over-year. Adjusted EBITDA1 was $28 million, up 66% year-over-year. Adjusted EBITDA margin1 expanded 9 percentage points year-over-year to 47%. Basic earnings per share (EPS) was $0.15, u
Interactive Brokers Offers Eligible Clients Access to the Anthropic, PBC Initial Public Offering13.11.2026 12:00:00 EET | Press release
Interactive Brokers Ireland Limited, part of Interactive Brokers Group (Nasdaq: IBKR), an automated global broker, today announced that eligible clients can participate in the initial public offering (the “Offering”) of Anthropic, PBC (the “Company”). Through the IBKR platform, eligible clients resident and located in Denmark, Finland, France, Germany, Ireland, the Netherlands, Norway, Spain, and Sweden can review the Offering and submit an application during the offer period, which is open for all eligible clients from 12 November, 2026 to 17 November, 2026. Participation is subject to eligibility criteria, allocation will be in accordance with the Company’s allocation policy, based on the number of shares we receive to distribute to our clients, and the terms set out in the Company’s prospectus. Allocation is not guaranteed. The Offering and the relevant documents are available on the IPO offering page at www.interactivebrokers.ie/en/trading/ipo/anthropic.php. How eligible clients ca
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 09:00:00 EET | Press release
Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s Radio City Music Hall and Intuit Dome in California. “People are seeking richer and more immersive e
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane ® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.3-6 The lower face plays a pivotal role in overall facial balance, influencing proportions and profile,4 with recent market research conducted by Galderma finding that the chin is the third most treated area in existing HA injectable users.7 In the chin, genetic factors and age-related changes can lead to reduced definition and poor projection.4,8 In the jawline, factors such as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom